Table 4.
Propensity score of high-impact group versus controls.
| Variable | LNZ High-impact (n = 11) | Controls (n = 33) | P | 95% CI Lower-Upper | ||
| Age, median (IQR) | 59 (55–78) | 62 (52–74) | .84 | – | ||
| Sex (males) | 7 (63.6) | 22 (66.6) | .85 | – | ||
| Comorbidities | ||||||
| Ischemic heart disease | 2 (18.2) | 14 (42.4) | .26 | – | ||
| Diabetes mellitus | 3 (27.3) | 5 (15.2) | .36 | – | ||
| Peripherical vascular disease | 2 (18.2) | 7 (21.2) | .82 | – | ||
| Neoplasia | 4 (36.4) | 5 (15.2) | .13 | – | ||
| Hepatic disease | 1 (9.1) | 1 (3.0) | .40 | – | ||
| Charlson index (median, IQR) | 5 (2–7) | 4 (1–7) | .47 | – | ||
| Type IE | ||||||
| Aortic | 3 (27.3) | 11 (33.3) | .70 | – | ||
| Mitral | 5 (45.5) | 9 (27.3) | .26 | – | ||
| Tricuspid | 3 (27.3) | 3 (9.1) | .12 | – | ||
| Pulmonary | 1 (9.1) | 2 (6.1) | .73 | – | ||
| Acquisition | ||||||
| Community | 3 (27.3) | 22 (66.6) | .01 | 0.17 (0.03–0.78) | ||
| Nosocomial | 7 (63.6) | 8 (24.2) | .04 | 5.25 (1.21–22.7) | ||
| Healthcare related | 1 (9.1) | 2 (6.0) | .72 | – | ||
| Etiology | ||||||
| S. aureus | 5 (45.5) | 12 (36.4) | .59 | – | ||
| Coagulase negative staphylococci | 5 (45.5) | 5 (15.2) | .09 | – | ||
| Enterococcus spp. | 0 | 3 (9.1) | .56 | – | ||
| Streptococcus spp. | 1 (9.1) | 5 (15.2) | .61 | – | ||
| Complications | ||||||
| Persistent bacteremia | 2 (20.0) | 6 (18.2) | .89 | – | ||
| Central nervous system involvement | 0 | 8 (24.2) | .08 | – | ||
| Renal failure | 4 (36.4) | 13 (39.4) | .85 | – | ||
| Septic shock | 2 (18.2) | 4 (12.1) | .61 | – | ||
| Cardiac surgery | 4 (36.4) | 14 (42.4) | .72 | – | ||
| Evolution | ||||||
| In-hospital mortality | 6 (54.5) | 6 (18.2) | .04 | 5.40 (1.22–23.72) | ||
| One-year follow-up mortality | 0 | 1 (3.0) | .56 | – | ||
| Overall mortality | 6 (54.5) | 7 (21.2) | .05 | 4.45 (1.04–19.01) | ||
| Median duration of treatment for IE (days, IQR) | 34 (19 – 46) | 37 (28 – 43) | .58 | – | ||
| Median in-hospital stay (days, IQR) | 34 (27 – 57) | 32 (27 – 44) | .37 | – | ||